TNXP Pemfailan SEC - Tonix Pharmaceuticals Holding Corp.- Laporan Tahunan, Penyata Proksi, Prospektus

Statistik Asas

LEI	529900ACPKP9QW20GX48
CIK	1430306

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Tonix Pharmaceuticals Holding Corp.

SEC Filings (Chronological Order)

Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.

September 4, 2025	S-3/A	As filed with the Securities and Exchange Commission on September 4, 2025 As filed with the Securities and Exchange Commission on September 4, 2025 Registration No.
September 4, 2025	EX-23.01	Tonix Pharmaceuticals Holding Corp. S-3/A Tonix Pharmaceuticals Holding Corp. S-3/A Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Amendment No. 1 to the Registration Statement of Tonix Pharmaceuticals Holding Corp. (the “Company”) on Form S-3 (No. 333-287965) to be filed on or about September 4, 2025 of our report dated March 18, 2025, on our audits of the conso
August 18, 2025	EX-99.01	Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 US Approval of Tonmya TM for the Treatment of Fibromyalgia August 18, 2025 NASDAQ: TNXP AGENDA + PARTICIPANTS Introduction, Fibromyalgia Overview & Tonmya TM Label Seth Lederman, M.D. – Chief Executive Officer and Chairman 01 02 03 Commercial and Go - To - Market Strategy Thomas Englese – EVP, Commercial & President, Tonix Medicines Q&A Seth Le
August 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 18, 2025 TONIX PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 18, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (
August 15, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 15, 2025 TONIX PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 15, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (
August 15, 2025	EX-99.01	Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years Fibromyalgia is a chronic pain condition that affects more than 10 million adults in the U.S. who are mostly women Two Pivotal Phase 3 studies demonstrated To TONIX PHARMACEUTICALS HOLDING CORP 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces FDA Approval of TonmyaTM (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years Fibromyalgia is a chronic pain condition that affects more than 10 million adults in the U.S. who are mostly women Two Pivo
August 11, 2025	EX-31.01	CERTIFICATION TONIX PHARMACEUTICALS HOLDING CORP 10-Q Exhibit 31.01 CERTIFICATION I, Seth Lederman, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under whi
August 11, 2025	EX-32.01	CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 TONIX PHARMACEUTICALS HOLDING CORP 10-Q Exhibit 32.01 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Seth Lederman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Tonix Pha
August 11, 2025	EX-99.01	Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights FDA PDUFA goal date of August 15, 2025, for TNX‑102 SL for fibromyalgia: if approved by FDA, TNX‑102 SL would be the first new drug for fibromyalgia in mor Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights FDA PDUFA goal date of August 15, 2025, for TNX‑102 SL for fibromyalgia: if approved by FDA, TNX‑102 SL would be the first new drug for fibromyalgia in more than 16 years  In June 2025, the Company was added to the Russell 3000® and Russell 2000® Inde
August 11, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-36019 TONIX PHAR
August 11, 2025	EX-31.02	CERTIFICATION TONIX PHARMACEUTICALS HOLDING CORP 10-Q Exhibit 31.02 CERTIFICATION I, Bradley Saenger, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under w
August 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 11, 2025 TONIX PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 11, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (
July 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 25, 2025 TONIX PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 25, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co
July 21, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 21, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co
July 21, 2025	EX-99.01	TONIX PHARMACEUTICALS HOLDING CORP. 8-K TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 FOR IMMEDIATE RELEASE Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia CHATHAM, N.J., July 21, 2025 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that Tonix Medicines, Inc.,
July 16, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 16, 2025 TONIX PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 16, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co
July 16, 2025	EX-99.01	TONIX PHARMACEUTICALS HOLDING CORP TONIX PHARMACEUTICALS HOLDING CORP Exhibit 99.01 © 2025 Tonix Pharmaceuticals Holding Corp. Corporate Presentation July 2025 NASDAQ: TNXP PO6091 July 2025 (Doc 1608 ) 2 © 2025 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are “forward
July 10, 2025	EX-99.2	TONIX PHARMACEUTICALS HOLDING CORP. 8-K TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.2 TNX - 801, A SINGLE - DOSE LIVE VACCINE PLATFORM FOR MPOX AND OTHER EMERGING VIRAL DISEASES: SAFETY, IMMUNOGENICITY, AND EFFICACY Sina Bavari, Ph.D. World Congress on Vaccines July 10 th , 2025 © 2025 Tonix Pharmaceuticals Holding Corp. 2 © 2025 Tonix Pharmaceuticals Holding Corp. DISCLAIMER "Certain statements in this presentation regarding str
July 10, 2025	EX-99.1	Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025 TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immu TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.1 Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025 TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in animals Subcutaneous
July 10, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 10, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co
July 9, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 9, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Com
July 9, 2025	EX-99.01	Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine The previously disclosed and now published RESILIENT data show that once-nightly TNX-102 Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine The previously disclosed and now published RESILIENT data show that once-nightly TNX-102 SL achieved statistically significant improvement in the primary endpoint of reducing fibromyal
July 9, 2025	EX-99.02	Pain Relief by Targeting Nonrestorative Sleep in Fibromyalgia: A Phase 3 Randomized Trial of Bedtime Sublingual Cyclobenzaprine Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.02 Pain Relief by Targeting Nonrestorative Sleep in Fibromyalgia: A Phase 3 Randomized Trial of Bedtime Sublingual Cyclobenzaprine Seth Lederman, MD1; Lesley M. Arnold, MD2; Ben Vaughn, MS3*; Jean M. Engels, MS1; Mary Kelley, MPH1; Gregory M. Sullivan, MD1 1Tonix Pharmaceuticals, Inc., Chatham, NJ, USA; 2University of Cincinnati College of Medicin
July 2, 2025	EX-99.01	Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models Combination treatment of mTNX-1700 (mTFF2-MSA fusion protein) with anti-PD1 antibody Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models Combination treatment of mTNX-1700 (mTFF2-MSA fusion protein) with anti-PD1 antibody was associated with increased survival and decreased metastases in animal models of gastric canc
July 2, 2025	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 2, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Com
June 16, 2025	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 16, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co
June 16, 2025	EX-99.02	Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.02
June 16, 2025	EX-99.01	Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025 TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal deliver Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025 TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia: FDA PDUFA goal date of August 15, 2025 TNX-102
June 13, 2025	EX-99.01	Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry, TONIX PHARMACEUTICALS HOLDING CORP 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry, including leadership roles at Validus Pharmaceuticals, Relialab and Novartis Led launch of Tonix
June 13, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 12, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co
June 12, 2025	EX-FILING FEES	Calculation of Filing Fee Table† Tonix Pharmaceuticals Holding Corp. S-3 Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) TONIX PHARMACEUTICALS HOLDING CORP. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(2) Proposed Maximum Offering Price Per Share(2) Maximum A
June 12, 2025	EX-4.04	Form of Senior Debt Indenture† Tonix Pharmaceuticals Holding Corp. S-3 Exhibit 4.04 TONIX PHARMACEUTICALS HOLDINGS CORP., as Issuer and ●, as Trustee INDENTURE Dated as of ● Senior Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between TONIX PHARMACEUTICALS HOLDINGS CORP. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and
June 12, 2025	EX-4.05	Form of Subordinated Debt Indenture† Tonix Pharmaceuticals Holding Corp. S-3 Exhibit 4.05 TONIX PHARMACEUTICALS HOLDINGS CORP., as Issuer and ●, as Trustee INDENTURE Dated as of ● Subordinated Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between TONIX PHARMACEUTICALS HOLDINGS CORP. and , as Trustee: Section of the Act Section of Indenture 310(a)(
June 12, 2025	S-3	As filed with the Securities and Exchange Commission on June 11, 2025 As filed with the Securities and Exchange Commission on June 11, 2025 Registration No.
June 12, 2025	EX-23.01	Consent of EisnerAmper LLP† Tonix Pharmaceuticals Holding Corp. S-3 Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement of Tonix Pharmaceuticals Holding Corp. (the “Company”) on Form S-3 to be filed on or about June 11, 2025 of our report dated March 18, 2025, on our audits of the consolidated financial statements as of December 31
June 11, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 11, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co
June 11, 2025	EX-1.01	Sales Agreement, dated June 11, 2025, by and between Tonix Pharmaceuticals Holdings Corp. and A.G.P./Alliance Global Partners Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 1.01 Tonix Pharmaceuticals Holding Corp. COMMON STOCK SALES AGREEMENT June 11, 2025 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 Ladies and Gentlemen: Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners, as follow
June 11, 2025	EX-10.1	Purchase Agreement, dated June 11, 2025, by and between Tonix Pharmaceuticals Holding Corp. and Lincoln Park Capital Fund, LLC † Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 10.01 PURCHASE AGREEMENT PURCHASE AGREEMENT (the “Agreement”), dated as of June 11, 2025, by and between TONIX PHARMACEUTICALS HOLDING CORP., a Nevada corporation (the “Company”), LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Compan
June 11, 2025	EX-10.02	Registration Rights Agreement, dated June 11, 2025, by and between Tonix Pharmaceuticals Holding Corp. and Lincoln Park Capital Fund, LLC † Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 10.02 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 11, 2025, by and between TONIX PHARMACEUTICALS HOLDING CORP., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms us
June 11, 2025	424B5	Up to $150,000,000 Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-282270 PROSPECTUS SUPPLEMENT (To Prospectus dated September 30, 2024) Up to $150,000,000 Common Stock On June 11, 2025, we entered into a certain sales agreement, or Sales Agreement, with A.G.P. / Alliance Global Partners, or A.G.P., relating to shares of our common stock offered by this prospectus. In accordance with the terms of the Sales Agr
June 11, 2025	EX-5.02	Consent of Brownstein Hyatt Farber Schreck, LLP (contained in Exhibit 5.02) Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 5.02 Brownstein Hyatt Farber Schreck, LLP 702.382.2101 main 100 North City Parkway, Suite 1600 Las Vegas, Nevada 89106 June 11, 2025 Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928 To the addressee set forth above: We have acted as local Nevada counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporatio
June 11, 2025	424B5	$75,000,000 and 48,708 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-282270 PROSPECTUS SUPPLEMENT (To Prospectus dated September 30, 2024) $75,000,000 and 48,708 Shares of Common Stock This prospectus supplement relates to the issuance and sale of up to $75,000,000 of shares of our common stock, or Purchase Shares, that we may sell to Lincoln Park Capital Fund, LLC, or Lincoln Park, from time to time pursuant to
June 11, 2025	EX-5.01	Consent of Brownstein Hyatt Farber Schreck, LLP (contained in Exhibit 5.01) Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 5.01 Brownstein Hyatt Farber Schreck, LLP 702.382.2101 main 100 North City Parkway, Suite 1600 Las Vegas, Nevada 89106 June 11, 2025 Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928 To the addressee set forth above: We have acted as local Nevada counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporatio
May 30, 2025	EX-23.01	Consent of EisnerAmper LLP* Tonix Pharmaceuticals Holding Corp. S-8 Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement of Tonix Pharmaceuticals Holding Corp. (the “Company”) on Form S-8 to be filed on or about May 30, 2025 of our report dated March 18, 2025, on our audits of the consolidated financial statements as of December 31,
May 30, 2025	EX-5.01	Consent of Brownstein Hyatt Farber Schreck, LLP (included in Exhibit 5.01)* Tonix Pharmaceuticals Holding Corp. S-8 Exhibit 5.01 Brownstein Hyatt Farber Schreck, LLP 702.382.2101 main 100 North City Parkway, Suite 1600 Las Vegas, Nevada 89106 May 30, 2025 Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928 To the addressee set forth above: We have acted as local Nevada counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporation
May 30, 2025	EX-FILING FEES	Filing Fee Table* Tonix Pharmaceuticals Holding Corp. S-8 Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) TONIX PHARMACEUTICALS HOLDING CORP. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Line Item Type Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Pri
May 30, 2025	S-8	As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 Registration No.
May 21, 2025	EX-99.01	Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress reaction (ASR) Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) Trial is sponsored by the University of North Carol
May 21, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 21, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Com
May 14, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 14, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Com
May 14, 2025	EX-99.01	Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations Mr. Hand brings more than 20 years of strategic legal and business leadership experience across multiple functions in the TONIX PHARMACEUTICALS HOLDING CORP Exhibit 99.1 Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations Mr. Hand brings more than 20 years of strategic legal and business leadership experience across multiple functions in the biopharmaceutical industry, including nearly a decade in senior executive positions at Celgene Served
May 12, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 12, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Com
May 12, 2025	EX-31.01	CERTIFICATION TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 31.01 CERTIFICATION I, Seth Lederman, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh
May 12, 2025	EX-99.01	Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treat TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Announced positive topline results from Phase 1 study of
May 12, 2025	EX-32.01	CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 TONIX PHARMACEUTICALS HOLDING CORP. 10-Q Exhibit 32.01 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Seth Lederman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Tonix Ph
May 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36019 TONIX PHA
May 12, 2025	EX-31.02	CERTIFICATION TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 31.02 CERTIFICATION I, Bradley Saenger, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
May 8, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 8, 2025 TONIX PHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 8, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Comm
April 29, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 29, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C
April 29, 2025	EX-99.01	Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-kil Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells TNX-1700 is in preclinical developm
April 29, 2025	EX-99.02	Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.02 Conclusion 1. Kim W, et al . PD - 1 Signaling Promotes Tumor - Infiltrating Myeloid - Derived Suppressor Cells and Gastric Tumorigenesis in Mice. Gastroenterology. 2021 Feb;160(3):781 - 796. 2.Veglia F, et al . Analysis of classical neutrophils and polymorphonuclear myeloid - derived suppressor cells in cancer patients and tumor - bearing mice.
April 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 25, 2025 TONIX PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 25, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C
April 24, 2025	EX-99.02	Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.02 A NOVEL SINGLE - DOSE, LIVE ATTENUATED, MINIMALLY REPLICATIVE MPOX VACCINE Farooq Nasar, Ph.D., M.P.H. WVC April 23, 2025 PO6066 April 23, 2025 (Doc 1583) © 2025 Tonix Pharmaceuticals Holding Corp. Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are “forward - looki
April 24, 2025	EX-99.01	Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised anima Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from a lethal challenge with clade IIa monkeypox virus Durability of TNX-801 vaccination show
April 24, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 23, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C
April 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 9, 2025 TONIX PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 9, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co
April 9, 2025	EX-99.01	Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies Agreement includes th TONIX PHARMACEUTICALS HOLDING CORP 8-K Exhibit 99.01 Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies Agreement includes the use of Tonix’s TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana’s
April 1, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 1, 2025 TONIX PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 1, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co
April 1, 2025	EX-99.01	Tonix Pharmaceuticals Launches TONIX ONETM, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition Tonix Pharmaceuticals 8k Exhibit 99.01 Tonix Pharmaceuticals Launches TONIX ONETM, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition Tonix expands its all-in-one platform, partnering with the world’s leading migraine diary app, enhancing disease education and prescription access CHATHAM, N.J., April 1, 2025 (GLOBE NEWSWIRE) – Tonix
March 31, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
March 24, 2025	EX-99.02	Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.02 © 2025 Tonix Pharmaceuticals Holding Corp. Corporate Presentation March 2025 NASDAQ: TNXP PO6052 March 21, 2025 (Doc 1569 ) 2 © 2025 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results a
March 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 24, 2025 TONIX PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 24, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C
March 24, 2025	EX-99.01	Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid anal Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more
March 21, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
March 18, 2025	EX-19.01	STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES Tonix Pharmaceuticals Holding Corp. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 19.01 STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES Tonix Pharmaceuticals Holding Corp. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES Two copies of this Statement of Company Policy on Insider Trading and Policy Regarding Special Trading Procedures (coll
March 18, 2025	EX-99.1	Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.1 Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Company expects to have sufficient cash
March 18, 2025	EX-10.57	Attachment A Statement of Work Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 10.57 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS PRIVATE OR CONFIDENTIAL. THE OMISSIONS HAVE BEEN INDICATED BY “[***].” Applied Technologies Center 315 Sigma Drive Summerville, SC 29486 www.ati.org PROJECT AGREEMENT NO.: 01 MCDC BASE AGREEMENT NO.: 2023-496 PROJECT TITLE: MCDC2215-006; D
March 18, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36019 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of r
March 18, 2025	EX-10.56	BASE AGREEMENT ADVANCED TECHNOLOGY INTERNATIONAL (ATI) 315 SIGMA DRIVE SUMMERVILLE, SC 29486 Tonix Pharmaceuticals. Inc. 26 Main Street Suite 101 Chatham, NJ 07928 Unique Entity Identifier (UEI): JYPLHNCHF675 Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 10.56 Page 1 of 52 BASE AGREEMENT BETWEEN ADVANCED TECHNOLOGY INTERNATIONAL (ATI) 315 SIGMA DRIVE SUMMERVILLE, SC 29486 AND Tonix Pharmaceuticals. Inc. 26 Main Street Suite 101 Chatham, NJ 07928 Unique Entity Identifier (UEI): JYPLHNCHF675 MEDICAL CBRN DEFENSE CONSORTIUM (MCDC) BASE AGREEMENT NO.: 2023-493 Authority: MCDC Other Transaction Agreement
March 18, 2025	EX-23.01	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements of Tonix Pharmaceuticals Holding Corp. on Form S-3 (Nos. 333-266982 and 333-282270) and Form S-8 (Nos. 333-202006, 333-212300, 333-219928, 333-226776, 333-232137, 333-239152, 333-257437, 333-265705, 333-272746, a
March 18, 2025	EX-4.06	Exhibit 4.06 Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 4.06 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary of all material characteristics of our common stock as set forth in our articles of incorporation and bylaws. The summary does not purport to be complete and is qualified in its entirety by reference to
March 18, 2025	EX-21.01	SUBSIDIARIES OF THE COMPANY Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 21.01 SUBSIDIARIES OF THE COMPANY Subsidiary Name State/ Jurisdiction of Incorporation/Formation Tonix Pharmaceuticals, Inc. Delaware Krele, LLC Delaware Tonix Pharmaceuticals (Canada), Inc. New Brunswick, Canada Tonix Pharma Holdings Limited Ireland Tonix Pharma Limited Ireland Jenner Institute LLC Delaware Tonix R&D Center, LLC Delaware Tonix Medi
March 18, 2025	EX-31.02	CERTIFICATION Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 31.02 CERTIFICATION I, Bradley Saenger, certify that: 1. I have reviewed this annual report on Form 10-K of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under whi
March 18, 2025	EX-97.01	TONIX PHARMACEUTICALS HOLDING CORP. COMPENSATION RECOVERY POLICY (Adopted and approved on November 14, 2023) Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 97.01 TONIX PHARMACEUTICALS HOLDING CORP. COMPENSATION RECOVERY POLICY (Adopted and approved on November 14, 2023) 1. Purpose Tonix Pharmaceuticals Holding Corp. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulation
March 18, 2025	EX-32.01	CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 32.01 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Seth Lederman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Tonix Pharm
March 18, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 18, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C
March 18, 2025	EX-31.01	CERTIFICATION Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 31.01 CERTIFICATION I, Seth Lederman, certify that: 1. I have reviewed this annual report on Form 10-K of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which
March 10, 2025	EX-99.02	Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Holding Corp. 8-K EXHIBIT 99.02 © 2025 Tonix Pharmaceuticals Holding Corp. Resurrecting Dr. Edward Jenner’s 1796 Horsepox Vaccine to Protect Against Mpox and Smallpox UT Southwestern Microbiology Department Seminar Seth Leder man, M.D. March 11, 2025 Version P06050 March 11, 2025 (Doc 1566) © 2025 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statem
March 10, 2025	EX-99.01	Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company’s Single-Dose Mpox and Smallpox Vaccine Candidate The World Health Organization (WHO) recently reaffirmed the spread of new clade Tonix Pharmaceuticals Holding Corp. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company’s Single-Dose Mpox and Smallpox Vaccine Candidate The World Health Organization (WHO) recently reaffirmed the spread of new clade Ib Mpox a public health emergency of international concern (PHEIC): second Mpox-related WHO PHEI
March 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 10, 2025 TONIX PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 10, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C
March 4, 2025	EX-99.02	Tonix Pharmaceuticals Form 8-K Tonix Pharmaceuticals Form 8-K Exhibit 99.02 © 2025 Tonix Pharmaceuticals Holding Corp. Controversies in Fibromyalgia 2025 NASDAQ: TNXP Version P06048 March 3, 2025 (Doc 1564 ) Transmucosal Sublingual Cyclobenzaprine (TNX - 102 SL) Treatment of Fibromyalgia at Bedtime to Target Non - Restorative Sleep Showed Durable Pain Reduction in Two Double - Blind Randomized Phase 3 Studies March 3, 2025 2 ©
March 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 27, 2025 TONIX PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 27, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
March 4, 2025	EX-10.01	Dated February 27, 2025 TONIX PHARMA LIMITED SIOBHAN FOGARTY CONTRACT OF EMPLOYMENT Table of Contents TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 10.01 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS PRIVATE OR CONFIDENTIAL. THE OMISSIONS HAVE BEEN INDICATED BY “[***].” Dated February 27, 2025 TONIX PHARMA LIMITED and SIOBHAN FOGARTY CONTRACT OF EMPLOYMENT Table of Contents 1 Definitions and interpretation 1 2 Appointment 1 3 Duties 1 4
March 4, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 3, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co
March 4, 2025	EX-99.01	Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal deliv Tonix Pharmaceuticals Form 8-K Exhibit 99.01 Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia TNX-102 SL demonstrated statistically significant impro
February 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 20, 2025 TONIX PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 20, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
February 7, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 7, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
February 7, 2025	EX-99.01	Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 Compan Tonix Pharmaceuticals Holding Corp 8-K Exhibit 99.01 Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 Company is debt-free after repaying mortgage on facilities TNX-102 SL fibromyalgia FDA PDUFA goal date
February 6, 2025	EX-99.01	Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases Results from the Phase 1 single as Tonix Pharmaceuticals Holding Corp 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases Results from the Phase 1 single ascending dose study support proceeding to develop a Phase 2 trial for the prevention of kidney tra
February 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 6, 2025 TONIX PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 6, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
February 6, 2025	EX-99.02	Tonix Pharmaceuticals Holding Corp 8-K Tonix Pharmaceuticals Holding Corp 8-K Exhibit 99.02 © 2025 Tonix Pharmaceuticals Holding Corp. Corporate Presentation February 2025 NASDAQ: TNXP PO6043 Feb 6, 2025 (Doc 1559 ) 2 © 2025 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results ar
February 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 3, 2025 TONIX PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 3, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
February 4, 2025	EX-99.01	Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer Ms. Fogarty has served at Tonix since 2016, most recently as Executive Vice President, Product Development Tonix is Preparing for Potential Launch of TNX-102 SL for the managem TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer Ms. Fogarty has served at Tonix since 2016, most recently as Executive Vice President, Product Development Tonix is Preparing for Potential Launch of TNX-102 SL for the management of fibromyalgia with U.S. FDA PDUFA goal date of August 15, 2025 CHATHAM, N.J., February 4,
February 3, 2025	EX-99.01	Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split Tonix Pharmaceuticals Form 8-K Exhibit 99.1 Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split CHATHAM, N.J., February 3, 2025 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it will effect a 1-for-100 reverse st
February 3, 2025	EX-10.01	Pay-Off Letter, dated February 3, 2025, by and among the Loan Parties, the Lenders and the JGB Agent Tonix Pharmaceuticals Form 8-K Exhibit 10.01 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS PRIVATE OR CONFIDENTIAL. THE OMISSIONS HAVE BEEN INDICATED BY “[***].” JGB Collateral LLC 246 Post Road East, 2nd Floor Westport, CT 06880 February 3, 2025 TONIX PHARMACEUTICALS HOLDING CORP. 26 Main Street Suite 101 Chatham, NJ 07928 Attention: Set
February 3, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 3, 2025 TONIX PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 3, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
January 8, 2025	EX-99.02	TONIX PHARMACEUTICALS HOLDING CORP. 8-K TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.02 © 2025 Tonix Pharmaceuticals Holding Corp. Corporate Presentation January 2025 NASDAQ: TNXP PO6037 January 8, 2025 (Doc 1553 ) 2 © 2025 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or result
January 8, 2025	EX-99.01	Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access Mr. Ainsworth brings over two decades of industry and market access experience to Tonix U.S. Food and Drug Admi TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access Mr. Ainsworth brings over two decades of industry and market access experience to Tonix U.S. Food and Drug Administration (FDA) recently assigned a Prescription Drug User Fee Act (PDUFA) goal date of August
January 8, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 8, 2025 TONIX PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 8, 2025 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (
December 23, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 23, 2024 TONIX PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 23, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
December 23, 2024	EX-99.01	Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia Tonix received FDA’s Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia Tonix received FDA’s Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track de
December 20, 2024	424B5	$250,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-266982 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 30, 2024) $250,000,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated July 30, 2024, filed as a part of our registration statement on Form S-3 (File No. 333-266982) (the “July 2024 Prospectus”), as previously supplemented by our prosp
December 20, 2024	EX-5.01	TONIX PHARMACEUTICALS HOLDING CORP. 8-K TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 5.01 Brownstein Hyatt Farber Schreck, LLP 702.382.2101 main 100 North City Parkway, Suite 1600 Las Vegas, Nevada 89106 December 20, 2024 Tonix Pharmaceuticals Holding Corp. 26 Main Street Chatham, New Jersey 07928 To the addressee set forth above: We have acted as local Nevada counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the
December 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 20, 2024 TONIX PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 20, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
December 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 17, 2024 TONIX PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 17, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
December 17, 2024	EX-99.1	Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review has been grant Tonix Pharmaceuticals Holding Corp 8-K Exhibit 99.1 Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review has been granted in the Day 74 Letter TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track
December 6, 2024	S-8	As filed with the Securities and Exchange Commission on December 6, 2024 As filed with the Securities and Exchange Commission on December 6, 2024 Registration No.
December 6, 2024	EX-23.01	Tonix Pharmaceuticals Holding Corp. S-8 Tonix Pharmaceuticals Holding Corp. S-8 Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement of Tonix Pharmaceuticals Holding Corp. (the “Company”) on Form S-8 to be filed on or about December 6, 2024 of our report dated April 1, 2024, on our audits of the consolidated financial statements as of December
December 6, 2024	EX-FILING FEES	Calculation of Filing Fee Tables FORM S-8 (Form Type) TONIX PHARMACEUTICALS HOLDING CORP. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Tonix Pharmaceuticals Holding Corp. S-8 Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) TONIX PHARMACEUTICALS HOLDING CORP. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Title of Securities To Be Registered Amount To Be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price Amount of Regis
December 3, 2024	EX-99.03	TONIX PHARMACEUTICALS HOLDING CORP. 8-KA TONIX PHARMACEUTICALS HOLDING CORP. 8-KA EXHIBIT 99.03 TNX - 102 SL Lead Indication : Fibromyalgia Additional Indication: Acute Stress Disorder NASDAQ: TNXP December 2024 © 2024 Tonix Pharmaceuticals Holding Corp. PO6027 December 3, 2024 (Doc 1539) Fibromyalgia Status: Two statistically significant Phase 3 studies completed; FDA granted Fast Track Designation • First pivotal Phase 3 study (RELIEF)
December 3, 2024	8-K/A	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 3, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation
December 3, 2024	EX-99.02	TONIX PHARMACEUTICALS HOLDING CORP. 8-KA TONIX PHARMACEUTICALS HOLDING CORP. 8-KA EXHIBIT 99.02
December 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 3, 2024 TONIX PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 3, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
December 3, 2024	EX-99.04	TONIX PHARMACEUTICALS HOLDING CORP. 8-K/A TONIX PHARMACEUTICALS HOLDING CORP. 8-K/A Exhibit 99.04 © 2024 Tonix Pharmaceuticals Holding Corp. TNX - 1500 Organ Transplant Rejection & Autoimmune Disorders NASDAQ: TNXP Version P06026 December 3, 2024 (Doc 1542) 2 © 2024 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objecti
December 3, 2024	EX-99.01	Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires Tonix appoints two executives with decades of experience successfully launching and commercializing new CNS products Bradley Raudabaugh, MBA, joins as Vice Presiden TONIX PHARMACEUTICALS HOLDING CORP 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires Tonix appoints two executives with decades of experience successfully launching and commercializing new CNS products Bradley Raudabaugh, MBA, joins as Vice President, Marketing, bringing over 25 years of marketing, sales and product planning experience to Tonix
November 14, 2024	SC 13G/A	TNXP / Tonix Pharmaceuticals Holding Corp. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
November 14, 2024	SC 13G/A	US8902608624 / Tonix Pharmaceuticals Holding Corp. / Alyeska Investment Group, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
November 13, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 13, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
November 13, 2024	EX-99.01	Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company’s Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals The World Health Organization (WHO) declare TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company’s Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals The World Health Organization (WHO) declared the spread of new Clade Ib Mpox a public health emergency of international concern (PHEIC): Se
November 12, 2024	EX-31.01	CERTIFICATION TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 31.01 CERTIFICATION I, Seth Lederman, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh
November 12, 2024	EX-99.01	Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies Granted Fast Track Design TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studies Granted Fast Track Designation by FDA in July 2024 for TNX-102 SL, a centrally-acting, non-opioid analgesic; Fibromyalgia
November 12, 2024	EX-32.01	CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Seth Lederman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Tonix Pharmaceuticals Holding Corp. o
November 12, 2024	EX-32.02	CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Bradley Saenger, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Tonix Pharmaceuticals Holding Corp.
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-36019 TONIX
November 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 12, 2024 TONIX PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 12, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
November 12, 2024	EX-31.02	CERTIFICATION TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 31.02 CERTIFICATION I, Bradley Saenger, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
November 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 8, 2024 TONIX PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 8, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
November 8, 2024	EX-99.01	Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 © 2023 Tonix Pharmaceuticals Holding Corp. © 2024 Tonix Pharmaceuticals Holding Corp. TNX - 1700 Gastric and Colorectal Cancers NASDAQ: TNXP Version PO6019 November 5, 2024 (Doc 1531 ) © 2023 Tonix Pharmaceuticals Holding Corp. 2 © 2024 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in thi
November 4, 2024	EX-99.01	Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya Proposed clinical study in Kenya intended to test Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya Proposed clinical study in Kenya intended to test the safety, tolerability, and immunogenicity of TNX-801, a vaccine being developed to prevent mp
November 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 4, 2024 TONIX PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 4, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
November 1, 2024	EX-99.02	Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.02
November 1, 2024	EX-99.01	Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 New data show tolerability and no evidence of spreading to blood or tissues even at high doses of Tonix’s attenuated live-virus, minimally re Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 New data show tolerability and no evidence of spreading to blood or tissues even at high doses of Tonix’s attenuated live-virus, minimally replicating vaccine candidate TNX-801 in immunocompromised animals TNX-801, has characteristics th
November 1, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 1, 2024 TONIX PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 1, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
October 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 30, 2024 TONIX PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 30, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
October 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 28, 2024 TONIX PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 28, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
October 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 17, 2024 TONIX PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 17, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
October 17, 2024	EX-99.01	Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA) First payment received under Tonix’s contract with the Defe TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA) First payment received under Tonix’s contract with the Defense Threat Reduction Agency (DTRA), for up to $34 million over five years CHATHAM, N.J., October
October 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 16, 2024 TONIX PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 16, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
October 16, 2024	SC 13G/A	TNXP / Tonix Pharmaceuticals Holding Corp. / Empery Asset Management, LP - TONIX PHARMACEUTICALS HOLDING CORP. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tonix Pharmaceuticals Holding Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 890260847 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursu
October 16, 2024	EX-99.01	Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA) NDA based on two Phase 3 studies of TNX-102 SL in fibromyalgia with statistically significant resu TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA) NDA based on two Phase 3 studies of TNX-102 SL in fibromyalgia with statistically significant results on the primary endpoint of reducing widespread pain; generally well tolerated TNX-102 SL is
October 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 8, 2024 TONIX PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 8, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (
October 8, 2024	EX-99.01	Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals AI (Artificial Intelligence) and ML (Machine Learning) drug discovery collaboration will accelerate the development of small molecules as orally availab TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals AI (Artificial Intelligence) and ML (Machine Learning) drug discovery collaboration will accelerate the development of small molecules as orally available host-targeted broad-spectrum medical countermeasures Host-directed antiviral drugs have the p
September 27, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 27, 2024 TONIX PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 27, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation
September 27, 2024	EX-99.01	Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines New patent expected to provide market exclusivity into 2036 Zembrace® SymTouch® (sumatriptan succinate i TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 99.01 Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines New patent expected to provide market exclusivity into 2036 Zembrace® SymTouch® (sumatriptan succinate injection) 10mg is indicated for the acute treatment of migraine in adults CHATHAM, N.J., Septemb
September 26, 2024	CORRESP	Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928 Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928 September 26, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Tonix Pharmaceuticals Holding Corp. Registration Statement on Form S-3 (File No. 333- 282270) Filed on September 20, 2024 Ladies and Gentlemen: In accordanc
September 23, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 23, 2024 TONIX PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 23, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation
September 23, 2024	EX-99.04	TONIX PHARMACEUTICALS HOLDING CORP. - 8-K TONIX PHARMACEUTICALS HOLDING CORP. - 8-K Exhibit 99.04 The importance of in vitro discriminatory tests in the development of a sublingual dosage form of TNX - 102 SL ( Cyclobenzaprine HCl) tablets Siobhan Fogarty , 1 Seth Lederman, MD, 1 Marino Nebuloni, 2 Bruce Daugherty, 1 1 Tonix Pharmaceuticals, Inc., Chatham, NJ, USA; 2 Redox SRL, Viale Stucchi, 62/26 20900 Monza Italy TNX - 102 SL is an inv
September 23, 2024	EX-99.01	Tonix Pharmaceuticals Announces Data Presentations on TNX-102 SL for Fibromyalgia at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024) Presentations highlighted the proprietary formulation technology and pharmaco TONIX PHARMACEUTICALS HOLDING CORP. - 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Data Presentations on TNX-102 SL for Fibromyalgia at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024) Presentations highlighted the proprietary formulation technology and pharmacokinetic properties of TNX-102 SL (sublingual cyclobenzaprine HCl) Composition and methods pate
September 23, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
September 23, 2024	EX-99.03	TONIX PHARMACEUTICALS HOLDING CORP. - 8-K TONIX PHARMACEUTICALS HOLDING CORP. - 8-K Exhibit 99.03 © 2024 Tonix Pharmaceuticals Holding Corp. Pharmacokinetic Properties of TNX - 102 SL, a Sublingual Formulation of Cyclobenzaprine Hydrochloride Bruce Daugherty, PhD 11 th Pharmaceutics and Novel Drug Delivery Systems (PDDS) Conference 2024 – Oral Presentation September 19, 2024 Rome, Italy Version 1513 September 12, 2024 (P0601) 2 © 2024 Ton
September 23, 2024	EX-99.02	TONIX PHARMACEUTICALS HOLDING CORP. - 8-K TONIX PHARMACEUTICALS HOLDING CORP. - 8-K Exhibit 99.02 Redox ©2024 Mannitol as a eutectic forming agent for improved sublingual delivery of Cyclobenzapine HCl Prof. Marino Nebuloni 11 th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS), Rome September 19, 2024. Oral Presentation. Redox ©2024 Disclosures • Prof . Nebuloni is an employee of Redox Analytical Science Srl • Re
September 20, 2024	EX-23.01	Consent of EisnerAmper LLP.   TONIX PHARMACEUTICALS HOLDING CORP. S-3   Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement of Tonix Pharmaceuticals Holding Corp. (the “Company”) on Form S-3 to be filed on or about September 20, 2024 of our report dated April 1, 2024, on our audits of the consolidated financial statements as of Dec
September 20, 2024	EX-5.01	Opinion of Brownstein Hyatt Farber Schreck, LLP.   TONIX PHARMACEUTICALS HOLDING CORP. S-3   Exhibit 5.01 Brownstein Hyatt Farber Schreck, LLP 702.382.2101 main 100 North City Parkway, Suite 1600 Las Vegas, Nevada 89106   September 20, 2024 Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928 To the addressee set forth above: We have acted as local Nevada counsel to Tonix Pharmaceuticals Holding Corp., a Nevada
September 20, 2024	EX-FILING FEES	Calculation of Filing Fee Table   TONIX PHARMACEUTICALS HOLDING CORP. S-3   Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Tonix Pharmaceuticals Holding Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Share (2) Max
September 20, 2024	EX-5.02	Opinion of Lowenstein Sandler, LLP. TONIX PHARMACEUTICALS HOLDING CORP. S-3 Exhibit 5.02 September 20, 2024 Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928 Re: Shelf Registration Statement of Tonix Pharmaceuticals Holding Corp. on Form S-3 Ladies and Gentlemen: We have acted as counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”), in connection with its filing o
September 20, 2024	S-3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) As filed with the Securities and Exchange Commission on September 20, 2024 Registration No.
September 19, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 19, 2024 TONIX PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 19, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation
September 19, 2024	EX-99.01	Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines New patent expected to expire in 2030 Tosymra® (sumatriptan nasal sp TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines New patent expected to expire in 2030 Tosymra® (sumatriptan nasal spray) 10mg is indicated and marketed for the acute treatment of migraine in adults CHATHAM, N.J.,
September 16, 2024	EX-99.01	Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO’s Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency The World Health Organization (WHO) released its preferre TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO’s Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency The World Health Organization (WHO) released its preferred target product profile (TPP) criteria for mpox vaccines at its Mpox Research and Innovation Sc
September 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 16, 2024 TONIX PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 16, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation
September 13, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
September 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 10, 2024 TONIX PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 10, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation
September 10, 2024	EX-99.01	Tonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial Operations Thomas brings more than 20 years of commercial and operations experience in the biopharmaceutical industry to Tonix Tonix is on track t Tonix Pharmaceuticals Holding Corp - 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial Operations Thomas brings more than 20 years of commercial and operations experience in the biopharmaceutical industry to Tonix Tonix is on track to submit an NDA for TNX-102 SL for fibromyalgia in October of 2024 CHATHAM, N.J., September 10,
September 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 6, 2024 TONIX PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 6, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
September 9, 2024	EX-99.02	© 2024 Tonix Pharmaceuticals Holding Corp. Using Synthetic Biology to Battle Mpox Symposium to Honor Prof. David Evans on His Retirement Seth Leder man, M.D. Version P0594 Sept 6, 2024 (Doc 1505) Exhibit 99.02 © 2024 Tonix Pharmaceuticals Holding Corp. Using Synthetic Biology to Battle Mpox Symposium to Honor Prof. David Evans on His Retirement Seth Leder man, M.D. Version P0594 Sept 6, 2024 (Doc 1505) © 2024 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for
September 9, 2024	EX-99.01	Tonix Pharmaceuticals Presented Data on the Potential Mpox Vaccine TNX-801 in “Using Synthetic Biology to Battle Mpox” Talk at Immunology Symposium at the University of Alberta TNX-801 vaccination demonstrated efficacy in protecting animals from leth Exhibit 99.01 Tonix Pharmaceuticals Presented Data on the Potential Mpox Vaccine TNX-801 in “Using Synthetic Biology to Battle Mpox” Talk at Immunology Symposium at the University of Alberta TNX-801 vaccination demonstrated efficacy in protecting animals from lethal challenge with clade I monkeypox and is in development as an mpox vaccine New data show improved tolerability in immunocompromised an
September 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 6, 2024 TONIX PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 6, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation)
August 30, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 30, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (
August 30, 2024	EX-5.01	Consent of Brownstein Hyatt Farber Schreck, LLP (included in Exhibit 5.01) Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 5.01 Brownstein Hyatt Farber Schreck, LLP 702.382.2101 main 100 North City Parkway, Suite 1600 Las Vegas, Nevada 89106 August 30, 2024 Tonix Pharmaceuticals Holding Corp. 26 Main Street Chatham, New Jersey 07928 To the addressee set forth above: We have acted as local Nevada counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “C
August 30, 2024	424B5	$150,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-266982 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 30, 2024) $150,000,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated July 30, 2024, filed as a part of our registration statement on Form S-3 (File No. 333-266982), or the Prior Prospectus. This prospectus supplement should be read i
August 29, 2024	EX-99.04	TONIX PHARMACEUTICALS HOLDING CORP. 8-K TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.04
August 29, 2024	EX-99.03	TONIX PHARMACEUTICALS HOLDING CORP. 8-K TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.03
August 29, 2024	EX-99.01	Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS) Investigator-initiated Ph TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS) Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress reaction (ASR)
August 29, 2024	EX-99.02	TONIX PHARMACEUTICALS HOLDING CORP. 8-K TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.02
August 29, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 29, 2024 TONIX PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 29, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (
August 26, 2024	EX-99.01	Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix’s Mpox Vaccine, TNX-801 World Health Organization declared spread of mpox in multiple African countries a public health emergency of international concer Tonix Pharmaceuticals Holding Corp - 8-K Exhibit 99.01 Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix’s Mpox Vaccine, TNX-801 World Health Organization declared spread of mpox in multiple African countries a public health emergency of international concern (PHEIC) for the second time in two years Worldwide availability and affordability of single-d
August 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 26, 2024 TONIX PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 26, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (
August 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 20, 2024 TONIX PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 20, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (
August 20, 2024	EX-99.01	Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication CATALYST is a Phase 2 single-blind, placebo-controlled, proof-of-concept study in patients presenting to the emerge Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication CATALYST is a Phase 2 single-blind, placebo-controlled, proof-of-concept study in patients presenting to the emergency department More than 27,569 individuals in the U.S. died from drug overdose deaths involving
August 19, 2024	EX-99.01	Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Highlights On track to submit NDA in second half 2024 for TNX-102 SL for fibromyalgia; completed successful pre-NDA meetings with FDA in second quarter 2024 FDA grant Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Highlights On track to submit NDA in second half 2024 for TNX-102 SL for fibromyalgia; completed successful pre-NDA meetings with FDA in second quarter 2024 FDA granted Fast Track designation for TNX-102 SL for fibromyalgia Commercial planning continues for U.S.
August 19, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 19, 2024 TONIX PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 19, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (
August 16, 2024	EX-31.02	CERTIFICATION TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 31.02 CERTIFICATION I, Bradley Saenger, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
August 16, 2024	EX-32.02	CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 32.02 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Bradley Saenger, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Tonix Pharmaceuticals Holding Corp.
August 16, 2024	EX-31.01	CERTIFICATION TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 31.01 CERTIFICATION I, Seth Lederman, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tonix Pharmaceuticals Holding Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh
August 16, 2024	EX-32.01	CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 TONIX PHARMACEUTICALS HOLDING CORP. 10-Q EXHIBIT 32.01 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Seth Lederman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Tonix Pharmaceuticals Holding Corp. o
August 16, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission file number: 001-36019 TONIX PHAR
August 15, 2024	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-36019 CUSIP NUMBER NOTIFICATION OF LATE FILING 890260847 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transit
August 12, 2024	EX-99.02	Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.02 Targeting Fibromyalgia Non - Restorative Sleep with Bedtime TNX - 102 SL (Sublingual Cyclobenzaprine HCl): Results of the Positive P hase 3 RESILIENT Trial Consistent with Syndromal Improvement Seth Lederman, MD 1 , Mary Kelley, MPH 1 , Ben Vaughn, MS, 2 Jean Engels, MS, 1 Gregory M. Sullivan, MD 1 1 Tonix Pharmaceuticals, Inc., Chatham, NJ, US
August 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 12, 2024 TONIX PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 12, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (
August 12, 2024	EX-99.01	Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain Bedtime TNX-102 SL (sublingual cyclobenzaprine HCl) treatment in the Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain Bedtime TNX-102 SL (sublingual cyclobenzaprine HCl) treatment in the Phase 3 RESILIENT study resulted in statistically significant improvement in the primary endpoin
August 9, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 9, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C
July 30, 2024	EX-1.01	Tonix Pharmaceuticals Holding Corp. COMMON STOCK SALES AGREEMENT Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 1.01 Tonix Pharmaceuticals Holding Corp. COMMON STOCK SALES AGREEMENT July 30, 2024 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 Ladies and Gentlemen: Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners, as follow
July 30, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 30, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co
July 30, 2024	EX-5.01	Tonix Pharmaceuticals Holding Corp. 8-K Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 5.01 Brownstein Hyatt Farber Schreck, LLP 702.382.2101 main 100 North City Parkway, Suite 1600 Las Vegas, Nevada 89106 July 30, 2024 Tonix Pharmaceuticals Holding Corp. 26 Main Street Chatham, New Jersey 07928 To the addressee set forth above: We have acted as local Nevada counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Com
July 30, 2024	424B5	Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-266982 PROSPECTUS SUPPLEMENT (To Prospectus dated August 26, 2022) Up to $50,000,000 Common Stock On July 30, 2024, we entered into a certain sales agreement, or Sales Agreement, with A.G.P. / Alliance Global Partners, or A.G.P., relating to shares of our common stock offered by this prospectus. In accordance with the terms of the Sales Agreeme
July 25, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 25, 2024 TONIX PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 25, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co
July 25, 2024	EX-99.01	Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia Fast Track is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need Fast Track designation for Tonmya Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia Fast Track is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need Fast Track designation for Tonmya recognizes fibromyalgia as a serious condition impacting more than 10 million U.S. adults NDA s
July 24, 2024	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 21, 2024 TONIX PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 21, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (C
July 16, 2024	EX-99.02	TONIX PHARMACEUTICALS HOLDING CORP. 8-K TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.02 © 2024 Tonix Pharmaceuticals Holding Corp. Broad - spectrum Host - directed Therapeutics: CD45 Inhibitor as Antiviral July 2024 NASDAQ: TNXP Version P0576 July 15 , 2024 (Doc 1476) 2 © 2024 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expec
July 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 16, 2024 TONIX PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 16, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co
July 16, 2024	EX-99.01	TONIX PHARMACEUTICALS HOLDING CORP. 8-K TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 © 2024 Tonix Pharmaceuticals Holding Corp. Corporate Presentation Abbreviated July 2024 NASDAQ: TNXP Version P0578 July 15 , 2024 (Doc 1475 ) 2 © 2024 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future opera
July 10, 2024	EX-99.01	Tonix Pharmaceuticals Announces Proposed Public Offering TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Proposed Public Offering CHATHAM, N.J., July 8, 2024 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants in lieu thereof)
July 10, 2024	EX-4.01	PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK TONIX PHARMACEUTICALS HOLDING CORP. TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 4.01 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK TONIX PHARMACEUTICALS HOLDING CORP. Warrant Shares: Original Exercise Date: July 10, 2024 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on
July 10, 2024	EX-99.03	TONIX PHARMACEUTICALS HOLDING CORP. 8-K TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.03 Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering CHATHAM, N.J., July 10, 2024 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced the closing of its public offering of 3,393,600 shares of its common stock and pre-fu
July 10, 2024	EX-5.02	-2- TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 5.02 July 10, 2024 Tonix Pharmaceuticals Holding Corp. 26 Main Street – Suite 101 Chatham, NJ 07928 Ladies and Gentlemen: We have acted as counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”) in connection with the sale and issuance of 3,393,600 shares of the Company’s common stock, par value $0.001 per share (the “Com
July 10, 2024	EX-10.01	SECURITIES PURCHASE AGREEMENT TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 9, 2024, between Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchaser
July 10, 2024	EX-5.01	TONIX PHARMACEUTICALS HOLDING CORP. 8-K TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 5.01 Brownstein Hyatt Farber Schreck, LLP 702.382.2101 main 100 North City Parkway, Suite 1600 Las Vegas, Nevada 89106 July 10, 2024 Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928 To the addressee set forth above: We have acted as local Nevada counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporatio
July 10, 2024	EX-4.02	WARRANT AGENT AGREEMENT Tonix Pharmaceuticals Holding Corp 8-K Exhibit 4.02 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of July 10, 2024 (the “Issuance Date”) between Tonix Pharmaceuticals Holding Corp., a company incorporated under the laws of the State of Nevada (the “Company”), and VStock Transfer, LLC (the “Warrant Agent”). WHEREAS, pursuant to the terms of that certain Placeme
July 10, 2024	EX-1.01	[SIGNATURE PAGE TO FOLLOW] Tonix Pharmaceuticals Holding Corp 8-K Exhibit 1.01 Dawson James Securities, Inc. 101 North Federal Highway Suite 600 Boca Raton, FL 33432 July 9, 2024 Ladies and Gentlemen: This letter (this “Agreement”) constitutes the agreement between Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”) and Dawson James Securities, Inc. (“Dawson”) pursuant to which Dawson shall serve as th
July 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 8, 2024 TONIX PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 8, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Com
July 10, 2024	EX-99.02	Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.02 Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering CHATHAM, N.J., July 9, 2024 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced it has entered into a placement agency agreement for the purchase and sa
July 9, 2024	424B5	Prospectus Supplement (To Prospectus dated August 26, 2022) 3,393,600 Shares of Common Stock Pre-Funded Warrants to Purchase up to 3,703,140 Shares of Common Stock Up to 3,703,140 Shares of Common Stock underlying such Pre-Funded Warrants Filed Pursuant to Rule 424(b)(5) Registration No. 333-266982 Prospectus Supplement (To Prospectus dated August 26, 2022) 3,393,600 Shares of Common Stock Pre-Funded Warrants to Purchase up to 3,703,140 Shares of Common Stock Up to 3,703,140 Shares of Common Stock underlying such Pre-Funded Warrants We are offering on a “reasonable best efforts” basis up to 3,393,600 shares of our common stock, par
July 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 8, 2024 TONIX PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 8, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Com
July 8, 2024	EX-99.01	Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia Approximately 10 milli TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia Approximately 10 million adults in the U.S. are affected by fibromyalgia, predominantly women NDA submission target co
July 8, 2024	424B5	Subject to Completion dated July 8, 2024 Preliminary Prospectus Supplement (To Prospectus dated August 26, 2022) Up to Shares of Common Stock Pre-Funded Warrants to Purchase up to Shares of Common Stock Up to Shares of Common Stock underlying such Pr Filed Pursuant to Rule 424(b)(5) Registration No. 333-266982 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities nor a solicitation of an offer to buy these securities in any jurisdiction where the offer and sale is not permitted. Subject to Com
July 1, 2024	8-K	Entry into a Material Definitive Agreement false 0001430306 0001430306 2024-06-28 2024-06-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 28, 2024	EX-99.03	Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.03 Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering CHATHAM, N.J., June 28, 2024 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced the closing of its public offering of 2,833,900 shares of its common stock and pre-fu
June 28, 2024	EX-5.01	TONIX PHARMACEUTICALS HOLDING CORP. 8-K TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 5.01 Brownstein Hyatt Farber Schreck, LLP 702.382.2101 main 100 North City Parkway, Suite 1600 Las Vegas, Nevada 89106 June 28, 2024 Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928 To the addressee set forth above: We have acted as local Nevada counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporatio
June 28, 2024	EX-99.02	Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.02 Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering CHATHAM, N.J., June 27, 2024 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced it has entered into a placement agency agreement for the purchase and s
June 28, 2024	EX-99.01	Tonix Pharmaceuticals Announces Proposed Public Offering TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Proposed Public Offering CHATHAM, N.J., June 26, 2024 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants in lieu thereof
June 28, 2024	EX-5.02	-2- TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 5.02 June 28, 2024 Tonix Pharmaceuticals Holding Corp. 26 Main Street – Suite 101 Chatham, NJ 07928 Ladies and Gentlemen: We have acted as counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”) in connection with the sale and issuance of 2,833,900 shares of the Company’s common stock, par value $0.001 per share (the “Com
June 28, 2024	EX-1.01	PLACEMENT AGENCY AGREEMENT Tonix Pharmaceuticals Holding Corp 8-K Exhibit 1.01 PLACEMENT AGENCY AGREEMENT Dawson James Securities, Inc. 101 North Federal Highway Suite 600 Boca Raton, FL 33432 June 27, 2024 Ladies and Gentlemen: This letter (this “Agreement”) constitutes the agreement between Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”) and Dawson James Securities, Inc. (“Dawson”) pursuant to wh
June 28, 2024	EX-4.01	PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK TONIX PHARMACEUTICALS HOLDING CORP. TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 4.01 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK TONIX PHARMACEUTICALS HOLDING CORP. Warrant Shares: Original Exercise Date: June 28, 2024 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on
June 28, 2024	EX-4.02	WARRANT AGENT AGREEMENT Tonix Pharmaceuticals Holding Corp 8-K Exhibit 4.02 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of June 28, 2024 (the “Issuance Date”) between Tonix Pharmaceuticals Holding Corp., a company incorporated under the laws of the State of Nevada (the “Company”), and VStock Transfer, LLC (the “Warrant Agent”). WHEREAS, pursuant to the terms of that certain Placeme
June 28, 2024	EX-10.01	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 27, 2024, between Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and
June 28, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events false 0001430306 0001430306 2024-06-27 2024-06-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 27, 2024	424B5	Prospectus Supplement (To Prospectus dated August 26, 2022) 2,833,900 Shares of Common Stock Pre-Funded Warrants to Purchase up to 4,228,158 Shares of Common Stock Up to 4,228,158 Shares of Common Stock underlying such Pre-Funded Warrants Filed Pursuant to Rule 424(b)(5) Registration No. 333-266982 Prospectus Supplement (To Prospectus dated August 26, 2022) 2,833,900 Shares of Common Stock Pre-Funded Warrants to Purchase up to 4,228,158 Shares of Common Stock Up to 4,228,158 Shares of Common Stock underlying such Pre-Funded Warrants We are offering on a “reasonable best efforts” basis 2,833,900 shares of our common stock, par value
June 26, 2024	EX-99.01	Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement CHATHAM, N.J., June 26, 2024 – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company, today announced that it has regained compliance with the minimum bid price requirement for continued listing on
June 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 26, 2024 TONIX PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 26, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co
June 26, 2024	424B5	Subject to Completion dated June 26, 2024 Preliminary Prospectus Supplement (To Prospectus dated August 26, 2022) Up to Shares of Common Stock Pre-Funded Warrants to Purchase up to Shares of Common Stock Up to Shares of Common Stock underlying such P Filed Pursuant to Rule 424(b)(5) Registration No. 333-266982 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities nor a solicitation of an offer to buy these securities in any jurisdiction where the offer and sale is not permitted. Subject to Com
June 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 20, 2024 TONIX PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 20, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co
June 20, 2024	SC 13G	US8902608624 / Tonix Pharmaceuticals Holding Corp. / L1 Capital Global Opportunities Master Fund, Ltd. - SCHEDULE 13G Passive Investment SC 13G 1 l1cap13g.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Tonix Pharmaceuticals Holding Corp. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 890260847 (CUSIP Number) June 12, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des
June 20, 2024	EX-99.01	Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya™ for the Management of Fibromyalgia Company aligned with FDA on key CMC topics Tonix also has completed the second and final pre-New Drug Application (NDA) meeting and d Tonix Pharmaceuticals Holding Corp. – 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya™ for the Management of Fibromyalgia Company aligned with FDA on key CMC topics Tonix also has completed the second and final pre-New Drug Application (NDA) meeting and discussed nonclinical, clinical pharmacology and clinical matters with the FDA, formal minutes
June 14, 2024	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 11, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction
June 14, 2024	EX-5.02	-2- Tonix Pharmaceuticals Holding Corp. 8-K/A Exhibit 5.02 June 13, 2024 Tonix Pharmaceuticals Holding Corp. 26 Main Street – Suite 101 Chatham, NJ 07928 Ladies and Gentlemen: We have acted as counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”) in connection with the sale and issuance of 1,199,448 shares of the Company’s common stock, par value $0.001 per share (the “C
June 13, 2024	EX-5.01	TONIX PHARMACEUTICALS HOLDING CORP. 8-K TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 5.01 Brownstein Hyatt Farber Schreck, LLP 702.382.2101 main 100 North City Parkway, Suite 1600 Las Vegas, Nevada 89106 June 13, 2024 Tonix Pharmaceuticals Holding Corp. 26 Main Street Chatham, New Jersey 07928 To the addressee set forth above: We have acted as local Nevada counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Com
June 13, 2024	EX-5.02	-2- TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 5.02 July [●], 2023 Tonix Pharmaceuticals Holding Corp. 26 Main Street – Suite 101 Chatham, NJ 07928 Ladies and Gentlemen: We have acted as counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”) in connection with the sale and issuance of [●] shares of the Company’s common stock, par value $0.001 per share (the “Common S
June 13, 2024	8-K	Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 11, 2024 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 001-36019 26-1434750 (State or Other Jurisdiction of Incorporation) (Co
June 13, 2024	EX-99.02	Tonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.02 Tonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering CHATHAM, N.J., June 12, 2024 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced it has entered into a placement agency agreement for the purchase and sale of 3,753,5
June 13, 2024	EX-99.01	Tonix Pharmaceuticals Announces Proposed Public Offering TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces Proposed Public Offering CHATHAM, N.J., June 11, 2024 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants in lieu thereof

TNXP / Tonix Pharmaceuticals Holding Corp. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Statistik Asas

SEC Filings

SEC Filings (Chronological Order)